MD1003-AMN MD1003 in Adrenomyeloneuropathy
MD1003 in Adrenomyeloneuropathy : a Randomized Double Blind Placebo Controlled Study
Sponsor: MedDay Pharmaceuticals SA
Listed as NCT02961803, this PHASE2/PHASE3 trial focuses on AMN and Adrenoleukodystrophy and remains completed. Sponsored by MedDay Pharmaceuticals SA, it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)AMN and progressive multiple sclerosis share some similarities including progressive spastic paraparesis and secondary energy failure leading to progressive axonal degeneration. Therefore, it was hypothesized that high doses of biotin might be efficient in patients with AMN.
AMN and progressive multiple sclerosis share some similarities including progressive spastic paraparesis and secondary energy failure leading to progressive axonal degeneration. Therefore, it was hypothesized that high doses of biotin might be efficient in patients with AMN.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MedDay Pharmaceuticals SA
For direct contact, visit the study record on ClinicalTrials.gov .